pyrazines has been researched along with Cancer of Skin in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.45) | 18.2507 |
| 2000's | 10 (32.26) | 29.6817 |
| 2010's | 19 (61.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basler, K; Cantù, C; Cecconi, V; Hafner, J; Hausmann, G; Restivo, G; Valenta, T; van den Broek, M; Zimmerli, D | 1 |
| Jue, MS; Park, E | 1 |
| Biskup, E; Gniadecki, R; Kamstrup, MR; Manfé, V | 1 |
| Biskup, E; Croce, CM; Gasparini, P; Gniadecki, R; Laganá, A; Manfè, V; Palmieri, D; Skov, AG; Willumsgaard, A; Woetmann, A; Ødum, N | 1 |
| Bonkobara, M; Hiroi, T; Ito, K; Iwata, T; Kobayashi, M; Kuroki, S; Kuroki, T; Mori, K; Nakagawa, T; Ono, K; Ozawa, Y; Sasaki, Y; Tetsuka, M; Washizu, T; Yamamoto, H | 1 |
| Reisman, SA | 1 |
| Chang, TP; Poltoratsky, V; Vancurova, I | 1 |
| Bocchia, M; Defina, M; Gozzetti, A | 1 |
| Amschler, K; Erpenbeck, L; Pletz, N; Schön, M; Schön, MP; Wallbrecht, K | 1 |
| Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y | 1 |
| Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM | 1 |
| Armstrong, JL; Birch-Machin, M; Fulda, S; Harbottle, A; Hill, DS; Hiscutt, EL; Kerr, R; Lovat, PE; Martin, S; Redfern, CP | 1 |
| Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ | 1 |
| Adini, I; Bischoff, J; Boscolo, E; Greenberger, S; Mulliken, JB | 1 |
| Arwert, EN; Driskell, RR; Goldie, SJ; Hoste, E; Mentink, RA; Quist, S; Watt, FM | 1 |
| Chang, HC; De La Rosa, M; Han, L; Lupov, IP; Oza, K; Pelloso, D; Robertson, MJ; Sahu, RP; Schwartz, A; Travers, JB; Voiles, L | 1 |
| Steiger, J; Zecher, D | 1 |
| Finke, J; Houet, L; Moeller, I; Spagnoli, GC; Veelken, H | 1 |
| Chan, DV; Gibson, HM; Hake, TS; Mishra, A; Porcu, P; Wong, HK | 1 |
| Adjei, AA; Albertini, M; Dawkins, F; Erlichman, C; Fitch, T; Fracasso, PM; Geyer, SM; Lorusso, P; Maples, W; Markovic, SN; Sharfman, W | 1 |
| Bachelez, H; Courtois, G; Dubertret, L; Jean-Louis, F; Laroche, L; Michel, L; Pellet, C; Sors, A | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Scheinfeld, N | 1 |
| Alinari, L; Baccarani, M; de Vivo, A; Derenzini, E; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Sabattini, E; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Chinnaiyan, AM; Fernandez, Y; Gratchouck, V; Jakubowiak, AJ; Nikiforov, MA; Riblett, M; Soengas, MS; Tang, WH; Varambally, S; Verhaegen, M; Zhuang, D | 1 |
| Casanova, JM; Dolcet, X; Egido, R; Llobet, D; Llombart, A; Marti, RM; Matias-Guiu, X; Pérez de Santos, AM; Schoenenberger, JA; Soria, X; Sorolla, A; Vilella, R; Yeramian, A | 1 |
| Chim, CS; Hwang, YY; Shek, TW | 1 |
| Baron, P; Polsky, B; Prochaska, HJ; Yeh, Y | 1 |
| Braguer, D; Briand, C; Carles, G; Garcia, P | 1 |
| Didolkar, MS; Eckardt, JR; Flaherty, LE; Samlowski, W; Sondak, VK; Taylor, SA; Unger, JM; Whitehead, RP | 1 |
3 review(s) available for pyrazines and Cancer of Skin
| Article | Year |
|---|---|
Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review.
Topics: Aged; Benzamides; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Nevus, Pigmented; Pyrazines; Skin Neoplasms | 2019 |
Future trends in organ transplant recipients--important issues for dermatologists.
Topics: Abatacept; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Forecasting; Graft Survival; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Organ Transplantation; Pyrazines; Recombinant Fusion Proteins; Risk Assessment; Rituximab; Skin Neoplasms | 2012 |
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Topics: Animals; Antineoplastic Agents; Benzoates; Boronic Acids; Bortezomib; Cyclosporine; Dasatinib; Deferasirox; Humans; Iron Chelating Agents; Ophthalmic Solutions; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Randomized Controlled Trials as Topic; Skin Diseases; Skin Neoplasms; Thiazoles; Triazoles | 2007 |
5 trial(s) available for pyrazines and Cancer of Skin
| Article | Year |
|---|---|
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome | 2010 |
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms | 2010 |
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Survival Rate; Treatment Failure | 2005 |
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Skin Neoplasms; Treatment Outcome | 2007 |
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Pyrazines; Pyridines; Skin Neoplasms; Survival Rate; Treatment Outcome | 2001 |
23 other study(ies) available for pyrazines and Cancer of Skin
| Article | Year |
|---|---|
WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma.
Topics: Acyltransferases; Animals; Carcinoma, Squamous Cell; Enzyme Inhibitors; Gene Expression Profiling; Humans; Membrane Proteins; Mice; Neoplastic Stem Cells; Papillomaviridae; Papillomavirus Infections; Pyrazines; Pyridines; Skin Neoplasms; Stem Cell Niche; Wnt Proteins; Wnt Signaling Pathway | 2018 |
Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Enzyme Inhibitors; Humans; Leupeptins; Lymphoma, T-Cell, Cutaneous; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptor, Notch1; Skin Neoplasms; Tumor Suppressor Protein p53 | 2013 |
cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Boronic Acids; Bortezomib; Chromatin Immunoprecipitation; Computational Biology; DNA Primers; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; In Situ Hybridization; Kaplan-Meier Estimate; Luciferases; Lymphoma, T-Cell; Mice; MicroRNAs; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Repressor Proteins; RNA, Small Interfering; Signal Transduction; Skin Neoplasms | 2013 |
The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Melanoma; Melanoma, Cutaneous Malignant; NF-kappa B; Proteasome Inhibitors; Pyrazines; Signal Transduction; Skin Neoplasms | 2013 |
Bortezomib: a therapeutic resource for the veterinary oncologist?
Topics: Animals; Boronic Acids; Bortezomib; Dog Diseases; Melanoma; Melanoma, Cutaneous Malignant; NF-kappa B; Proteasome Inhibitors; Pyrazines; Signal Transduction; Skin Neoplasms | 2013 |
Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Proteins; Interleukin-10; Interleukin-17; Interleukin-8; Lymphoma, T-Cell, Cutaneous; Models, Genetic; NF-kappa B; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Skin Neoplasms; Transforming Growth Factor beta1 | 2015 |
Cutaneous myeloma and bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Skin Neoplasms; Treatment Outcome | 2009 |
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Lung Neoplasms; Melanoma; Mice; NF-kappa B; Oxazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyridines; Skin Neoplasms | 2010 |
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide | 2010 |
Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Female; Fenretinide; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; In Vitro Techniques; Male; Melanoma; Middle Aged; Mutation; Nevus, Pigmented; Proto-Oncogene Proteins B-raf; Pyrazines; RNA, Small Interfering; Skin Neoplasms; Stress, Physiological; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Child; Child, Preschool; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Male; Molecular Targeted Therapy; Neoplastic Stem Cells; Neoplastic Syndromes, Hereditary; NF-kappa B; Pyrazines; Skin Neoplasms; Vascular Endothelial Growth Factor A | 2010 |
Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation.
Topics: Animals; Carcinoma, Squamous Cell; Cells, Cultured; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Epidermis; Epithelial Cells; Fibroblasts; Gene Expression; Humans; Interleukin-1alpha; Keratinocytes; Male; MAP Kinase Kinase 1; Mice; Mice, Inbred C57BL; Mice, Transgenic; Papilloma; Pyrazines; Sitagliptin Phosphate; Skin Neoplasms; Stromal Cells; Triazoles; Up-Regulation | 2012 |
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Carmustine; Cells, Cultured; Drug Interactions; Etoposide; Flow Cytometry; Gene Expression; Humans; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Lymphoma; Melanoma; Mice; Mice, Inbred C57BL; Protein Biosynthesis; Pyrazines; RNA Stability; Skin Neoplasms; STAT4 Transcription Factor; Ubiquitin | 2011 |
Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Topics: Antigen-Antibody Complex; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Gamma Rays; Humans; Melanoma; Multiple Myeloma; Neoplasm Proteins; Pinocytosis; Pyrazines; Skin Neoplasms; Treatment Outcome | 2012 |
Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; CTLA-4 Antigen; Female; GATA3 Transcription Factor; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lymphocyte Culture Test, Mixed; Male; Middle Aged; Polyubiquitin; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Pyrazines; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes | 2013 |
News & views in ... Immunotherapy.
Topics: Allergens; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cattle; Female; Glycogen Storage Disease Type II; Human papillomavirus 16; Human papillomavirus 18; Humans; Hypersensitivity; Immunotherapy; Leukotriene B4; Melanoma; Milk; Milk Proteins; Papillomavirus Infections; Pyrazines; Receptors, Leukotriene B4; Skin Neoplasms; Tumor Escape; Uterine Cervical Neoplasms; Viral Vaccines | 2012 |
Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell, Cutaneous; Middle Aged; NF-kappa B; NF-kappa B p50 Subunit; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sezary Syndrome; Skin Neoplasms; Transcription Factor RelA | 2006 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Boronic Acids; Bortezomib; Drug Design; E2F1 Transcription Factor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanocytes; Melanoma; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; RNA Interference; RNA, Messenger; Skin Neoplasms; Transcriptional Activation; Tumor Suppressor Protein p53 | 2007 |
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Female; Humans; Male; Melanoma; Protease Inhibitors; Pyrazines; Skin Neoplasms; Treatment Outcome | 2008 |
Multiple myeloma with testicular involvement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Male; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Radiography; Skin Neoplasms; Testicular Neoplasms; Treatment Outcome | 2008 |
Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Glutathione; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Lymphoma, T-Cell, Cutaneous; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Pyrazines; Reverse Transcriptase Inhibitors; Skin Neoplasms; Thiones; Thiophenes; Time Factors; Tumor Cells, Cultured; Virus Replication; Zidovudine | 1993 |
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |